Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Orlando, FL
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Atlanta, GA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Lake Charles, LA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Austin, TX
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Houston, TX
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network, LLC (Investigator Site File Location)
mi
from
Garden Grove, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network, LLC (Investigator Site File Location)
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Excell Research, Inc.
mi
from
Oceanside, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
NRC Research Institute
mi
from
Orange, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
mi
from
San Diego, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Alexian Brothers Centers for Psychiatric Research
mi
from
Hoffman Estates, IL
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Alexian Brothers Centers for Psychiatric Research
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Chinmay K. Patel, D.O.
mi
from
Hoffman Estates, IL
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Chinmay K. Patel, D.O.
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
CBH Health, LLC
mi
from
Gaithersburg, MD
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
CBH Health, LLC
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Hassman Research Institute
mi
from
Berlin, NJ
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Hassman Research Institute
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
CRI Worldwide
mi
from
Marlton, NJ
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
CRI Worldwide
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Pillar Clinical Research, LLC
mi
from
Dallas, TX
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
San Fernando Mental Health Center
mi
from
San Fernando, CA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
San Fernando Mental Health Center
mi
from
San Fernando, CA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Santa ClaritaMental Health Center
mi
from
Santa Clarita, CA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Santa ClaritaMental Health Center
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Mental Health Center of Denver
mi
from
Denver, CO
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Mental Health Center of Denver
mi
from
Denver, CO
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
United Services Inc.
mi
from
Willimantic, CT
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
United Services Inc.
mi
from
Willimantic, CT
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Life management Center of Northwest Florida
mi
from
Panama City, FL
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Life management Center of Northwest Florida
mi
from
Panama City, FL
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Central Fulton Community Mental Health Center
mi
from
Atlanta, GA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Central Fulton Community Mental Health Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Cobb County Community Services Board
mi
from
Austell, GA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Cobb County Community Services Board
mi
from
Austell, GA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Park Center
mi
from
Fort Wayne, IN
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Park Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Community Mental Health Center, Inc.
mi
from
Lawrenceburg, IN
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Community Mental Health Center, Inc.
mi
from
Lawrenceburg, IN
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Eyerly Ball
mi
from
Des Moines, IA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Eyerly Ball
mi
from
Des Moines, IA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Terrebonne Mental Health Center
mi
from
Houma, LA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Terrebonne Mental Health Center
mi
from
Houma, LA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
River Parish Mental Health Center
mi
from
LaPlace, LA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
River Parish Mental Health Center
mi
from
LaPlace, LA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Catholic Social Services of Washtenaw County (CSSW)
mi
from
Ann Arbor, MI
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Catholic Social Services of Washtenaw County (CSSW)
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Touchstone innovare
mi
from
Grand Rapids, MI
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Touchstone innovare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Clinton-Eaton-Ingham Community Mental Health Authority
mi
from
Lansing, MI
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Clinton-Eaton-Ingham Community Mental Health Authority
mi
from
Lansing, MI
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Human Development Center
mi
from
Duluth, MN
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Human Development Center
mi
from
Duluth, MN
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
North Point Health and Wellness
mi
from
Minneapolis, MN
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
North Point Health and Wellness
mi
from
Minneapolis, MN
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Pine Belt Mental Health Clinic
mi
from
Hattiesburg, MS
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Pine Belt Mental Health Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Burrell Behavioral Health
mi
from
Columbia, MO
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Burrell Behavioral Health
mi
from
Columbia, MO
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
UMKC School of Pharmacy
mi
from
Kansas City, MO
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
UMKC School of Pharmacy
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Community Mental Health Center of Lancaster County
mi
from
Lincoln, NE
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Community Mental Health Center of Lancaster County
mi
from
Lincoln, NE
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Greater Nashua Mental Health Center @ Community Council
mi
from
Nashua, NH
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Greater Nashua Mental Health Center @ Community Council
mi
from
Nashua, NH
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Saint Clare's Hospital
mi
from
Denville, NJ
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Saint Clare's Hospital
mi
from
Denville, NJ
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
University of New Mexico Department of Psychiatry UNM Health Sciences Center
mi
from
Albuquerque, NM
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
University of New Mexico Department of Psychiatry UNM Health Sciences Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials